Nutriband Inc. (NASDAQ: NTRB), a company focused on developing transdermal pharmaceutical products, announced that its CEO, Gareth Sheridan, will attend the inaugural Nasdaq LaB Biotech Summit on September 16, 2026, at the Nasdaq MarketSite in New York. The summit is designed to bring together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking, providing a platform for emerging companies to showcase their innovations to a broader financial audience.
This event comes at a pivotal time for Nutriband, as the company continues to advance its lead product, an abuse-deterrent fentanyl patch that incorporates its proprietary AVERSA™ technology. The AVERSA™ technology is designed to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, a critical feature in the ongoing battle against opioid addiction. By integrating this technology into any transdermal patch, Nutriband aims to enhance the safety profile of opioid-based therapies, addressing a significant public health concern.
The Nasdaq LaB Biotech Summit is expected to attract key stakeholders from the biotech sector, offering Nutriband a valuable opportunity to engage with potential investors and partners. Gareth Sheridan's participation underscores the company's commitment to raising awareness about its innovative approach to drug safety. The summit also serves as a networking hub, facilitating discussions that could lead to strategic collaborations or funding opportunities for Nutriband as it moves closer to commercialization.
Nutriband's focus on abuse-deterrent formulations is particularly relevant in light of the ongoing opioid crisis, which has prompted regulatory agencies to encourage the development of such technologies. The company's AVERSA™ technology could potentially be licensed to other pharmaceutical companies seeking to enhance the safety of their own transdermal products, thereby expanding Nutriband's revenue streams beyond its proprietary pipeline.
Investors and industry observers will be watching closely to see if any announcements emerge from the summit regarding Nutriband's development milestones or partnership discussions. The company's participation in high-profile events like the Nasdaq LaB Biotech Summit is a clear signal of its proactive approach to building visibility and credibility in the biotech investment community.
For more information about Nutriband and its technologies, visit the company's website at www.nutriband.com. The latest news and updates on NTRB can be found in the company's newsroom at https://ibn.fm/NTRB.
This announcement was made via a press release distributed by BioMedWire, a specialized communications platform focused on the biotechnology and life sciences sectors. The full press release is available at https://ibn.fm/j4F3R.
